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Toll-like receptor family (TLRs), pattern recognition receptors, is expressed not only on immune cells but also on
non-immune cells, including cardiomyocytes, fibroblasts, and vascular endothelial cells. One main function of TLRs
in the non-immune system is to regulate apoptosis. TLRs are the central mediators in hepatic, pulmonary, brain, and renal
ischemic/reperfusion (I/R) injury. Up-regulation of TLRs and their ligation by either exogenous or endogenous
danger signals plays critical roles in ischemia/reperfusion–induced tissue damage. Conventional TLR-NF-κB pathways are
markedly activated in failing and ischemic myocardium. Recent studies have identified a cross talk between TLR activation
and the PI3K/Akt pathway. The activation of TLRs is proposed to be the most potent preconditioning method
after ischemia, to improve the cell survival via the mechanism involved the PI3K/Akt signaling pathway and to
attenuate the subsequent TLR-NF-κB pathway stimulation. Thus, TLRs could be a great target in the new treatment
approaches for myocardial I/R injury.
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Introduction
Toll-like receptors (TLRs), the first line of host defense
against microbial infection, play a pivotal role in the induc-
tion of both innate and adaptive inflammatory responses.
However, recent evidence suggests that TLR-mediated in-
nate and immune responses contribute to organ ischemia/
reperfusion (I/R) injury [1]. In hemodynamic stresses and in
the response of pressure overloads, TLRs are activated in re-
sponse to ligands and initiating an immune response [1–4].
TLRs are the evolutionarily conserved transmembrane
receptors that recognize conserved microbial motifs called
pathogen associated molecule patterns (PAMPs). PAMPs
include bacterial lipopolysaccharide (LPS, recognized by
TLR4), lipoteichoic acid (recognized by TLR2), unmethy-
lated CpG-DNA (recognized by TLR9), and single or
double stranded RNA (recognized by TLR3) [2–5]. TLRs* Correspondence: drbaghi7272@yahoo.com
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creativecommons.org/publicdomain/zero/1.0/also recognize endogenous ligands called damage-
associated molecule patterns (DAMPs), which are released
from body cells under pathological conditions [1–4].
DAMPs include heparan sulfate, hyaluronic acid, fi-
brinogen, high mobility group box 1 (HMGB1), heat
shock proteins (HSPs) and oxidized phospholipids [6].
DAMPs interact with TLRs, resulting in activation of
MyD88- dependent nuclear factor-κB (NF-κB) signaling
pathway. NF-κB is an important transcription factor that
regulates numerous gene expression including inflamma-
tory cytokines, such as TNF-α, IL-1ß and IL-6, etc. [7, 8].
TLRs also activate MyD88- independet signaling pathway,
resulting in the production of interferons [1, 2, 5].TLR ligands induce protection against I/R injury through a
preconditioning and/or activation of PI3K/Akt dependent
mechanisms
TLRs are the key players in pathogenesis of I/R injuries in
heart, brain, liver, renal and rejection of transplants [9, 10].
Activation of TLR-mediated innate immune and inflam-
matory responses after reperfusion results in a positive
feedback loop characterized by an accelerated cytokines article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
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tion to the ischemic/reperfused site. The enhanced inflam-
matory status in the inflamed organ depresses cell
function and leads to cell damaged and organ failure [8,
10, 11]. Therefore, TLRs are assumed as potential targets
for therapeutic approaches in I/R injuries.
Interestingly, recent studies have shown that stimulation
of TLR2/3/9 by their ligands will induce cardiac protection
through ischemic or anesthetic preconditioning mecha-
nisms [10–13]. In addition, TLR2, TLR4, and TLR9 ligands
have also been reported to induce a protection against
ischemic injury through preconditioning mechanisms
[7, 14–17]. Through preconditioning mechanism, TLR
ligands can activate phosphoinositide 3 kinase (PI3K)
signaling [9, 16–18]. PI3Ks and its downstream target
serine serin /threonine kinase Akt (PKB), are a conserved
family of signal transduction enzymes which constitute an
endogenous negative feedback regulator and/or compensa-
tory mechanism, limits pro-inflammatory and apoptotic
events in response to injurious stimuli, prevents cardiac
myocyte apoptosis and protects myocardium from I/R in-
juries [17, 19, 20]. Several studies have identified cross talks
between TLR signaling and the PI3K/Akt pathway
[9, 17–19, 21]. Activation of PI3K/Akt involves the
survival pathway of IGF-I signaling and leads to activation
of anti-apoptotic and protective genes. In particular, data
demonstrate that TLR-induced cardioprotection is medi-
ated through activation of both PI3K/Akt and MEK/ERK
dependent mechanisms. Activation of PI3K/Akt signaling
has been shown to prevent cardiac myocyte apoptosis and
protect the myocardium from I/R injury [11, 13, 17–19].
PI3K/Akt pathway phosphorylates ERK pathway and fac-
tors Bim/BCL2. Activation of PI3K/Akt inhibits Bax con-
formational change, thus preventing Bax translocation and
integration into mitochondrial membrane. PI3K/Akt activa-
tion also phosphorylates Bim, leading to dissociation of
Bim from BCL2. Accordingly, PI3K inhibition abolishes
TLR-induced cardioprotection following I/R injury. PI3K/
Akt signaling induces an anti-apoptotic function through a
mechanism involving Raf/MEK/ERK pathway and Bim/
BCL2/Bax factors. Increased level of phospho-ERK involves
activation of ERK signaling. ERK can be activated by Ref-
mediated MEK signaling. The Raf/MEK/ERK signaling
pathway phosphorylates Bad, resulting in its inactivity. This
process allows BCL2 to form homodimers and process an
anti-apoptotic response. Activation of Raf/MEK/ERK also
induces Bim phosphorylation, resulting in Bim disassoci-
ation from BCL2. BCL2 then binds to Bax and prevents
Bax formation of homodimers and activation. The PI3K/
Akt and Raf/MEK/ERK signaling pathways are synergistic-
ally regulated by TLR activation and there is a crosstalk be-
tween both signaling pathways [11, 13, 17–19, 22].
Accordingly, preconditioning administration of small doses
of TLR synthetic ligands, induces a protection against I/Rinjury in heart and brain [11, 13, 17, 18, 23, 24]. The protec-
tion would be through a special anti-apoptotic cross talking
mechanism between PI3Ks and NF-κB signaling pathways.
Activation of PI3K/Akt-dependent signaling has been
shown to limit pro-inflammatory and apoptotic events in
response to injurious stimuli by an endogenous compensa-
tory mechanism to protect the myocardium from I/R injury
(Fig. 1) [9, 14–17].
Intriguingly, there are several reports of animal
models demonstrating that prior administration of sub-
lethal doses of TLR ligands protects against subsequent
lethal I/R injuries. They confer a “preconditioning-like”
mechanism, similar to those observed in ischemic or
anesthetic preconditioning [4, 16, 17, 19, 23, 24]. The
cardioprotective effects of TLR agonists have been ad-
dressed to induction of PI3K/Akt signaling pathway.
The studies have clarified a cross talk between TLR and
PI3K/Akt signaling pathways [16, 17, 19, 25].
The mentioned studies declare that TLR-cardiac pre-
conditioning would be a well-documented treatment to
trigger endogenous survival network to protect the heart
against I/R injuries [1, 4, 11, 26, 27].
TLR4 programed activation as a strategy to trigger the
survival pathway in I/R injury
In the solid organ transplantation, TLRs play provital
role in promoting graft rejection [1].
Accordingly, systemic and intra-graft inflammatory re-
sponses that occur during I/R event, would be markedly
reduced in the programmed signaling of TLR4. Pro-
grammed activation of TLR4 confers a potent cardiac
protection against I/R injury via a MyD88-dependent
mechanism [25, 28].
TLR4 signaling on both donor and recipient cell types
would mediate the robust early inflammatory responses
that occur after I/R condition [19, 29]. The inflammatory
reactions occur through reperfusion event whose the out-
come is further tissue injury. The degree of tissue injury is
especially dependent on the excessive ROS/RNS produc-
tion during reperfusion, and is dependent on the anoxic
phase. The reperfusion phase is well characterized by tissue
infiltration of neutrophils and monocytes, cytokine release,
complement deposition, endothelial dysfunction, along
with activation of platelet and coagulation cascade [19, 30].
In early inflammation of I/R phase after transplant-
ation, contribution of TLR4-putative activator HMGB1
is required, as well as, the co-receptor CD14 and the
intracellular adaptor proteins MyD88 and Trif [31–33].
TLR4 become activated in the presence of endogenous
molecules DAMPs, in particular HMGB1, released from
damaged cells or ischemic/reperfused tissues [1].
The remarkable dependency of TLR4 on HMGB1 in I/
R injury of cold organ preservation and transplantation,
but not on the other endogenous ligands, such as
Autocrine/Paracrine  
apoptotic signals
Growth factors, Survival 
signals
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Fig. 1 All TLRs signal through the common MyD88-dependent pathway. MyD88 signals via downstream kinases eventually leading to the activation of
NF-κB and inflammatory cytokine production. TLR preconditioning triggers cross activation of both MyD88-dependent and Trif-dependent pathways
with PI3K/Akt to protect the heart against I/R injury. TLR activation initiates an adaptive immune respons to maintain organ function through both the
PI3K survival and NF-κB signaling pathways and moderate expression of proinflammatory cytokines IL-1 ß, IL-6, and TNF-α. Activation of PI3K/
Akt signaling limits pro-inflammatory and apoptotic events induced by TLR-NF-κB pathway through an endogenous compensatory mechanism and
protects against I/R injuries. But, exaggerated activation of TLRs leads to a positive-feedback-regulation loop in inflammatory pathway and
robuset activation of TLR-NF-κB, which subsequently results in cardiac injury and heart impairment
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tially considered [34]. After I/R of the grafts, HMGB1
reveals a striking translocation out of the nucleus from
damaged cells. In several models of I/R injury, adminis-
tration of neutralizing antibodies against HMGB1 ameli-
orate the inflammatory response via systemic reducing
of IL-6 and TNFα and ICAM-1 expression [31–33].
Also, a combination treatment with brief doses of anti-
inflammatory and antiatherogenic agents Serp-1 and
CsA causes indefinite graft survival with normalhistology. The treatment has been defined to attenuate
TLR2, TLR4 responces through repressing the expres-
sion of signaling mediator MyD88 [19]. Notable, in the
absence of MyD88, transplantation of skin grafts across
minor histocompatibility antigens is possible [35].
In this aspect, the mechanism by which TLRs mediate
inflammatory responses after I/R, is mainly depended on
MyD88 which is very critical in the pathway. However,
both Trif and MyD88 must be absent to permit trans-
plantation across major histocompatibility barriers [1].
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MyD88-dependent pathway. MyD88 signals via IRAK-1
and other downstream kinases including IKKβ and IκB,
eventually leading to the activation of NF-κB and inflam-
matory cytokine production. TLR3 exclusively, and
TLR4 partly signals via Trif-dependent pathway [36].
In the presense of exaggerated activation of TLRs and in
a positive feedback loop in the heart for example, the path-
way becomes impaired and leads to heart failure [37, 38].
The molecular mechanisms by which TLRs mediate the in-
duction of adaptive heart failure, in response to pressure
overload and ventricle wall stresses, is accordingly through
the substantially robust activation of NF-κB pathway
[12, 39]. While, systemic deficiency of TLR signalling
for example, TLR2, TLR4, or intermediate signaling mol-
ecule MyD88, leads to attenuated myocardial inflammation,
smaller infarction size, and better preserved ventricular
function after ischemic injury [40, 41].
However, consistantly several studies have reported
that programmed preconditioning with TLR ligands trig-
gers cardiac protection against I/R injuries, in a menner
mimicing the ischemic/anesthetic cardiac precondition-
ing [1, 4, 11].
Remarkably, the cardioprotective effect of TLR ligand
preconditioning usually occurs between 12 and 24 h after a
small dose administration of ligand. According to refer-
ences, it is assumed that TLR preconditioning triggers cross
activation of both MyD88-dependent and Trif-dependent
pathways with PI3K/Akt to protect the heart against I/R in-
jury (Figs. 1 and 2), which is abolished by cycloheximide,
suggesting a mechanism involving de novo synthesis of car-
dioprotective proteins [4, 17, 19, 42].
Additinally, the survival pathway PI3K/Akt have in turn a
cross talk with both the extracellular signal-regulated kinase
1/2 (ERK1/2) and IκB kinase β (IKKβ) pathways, which is
known to be respocible for the LPS-induced TLR4 cardiac
protective effects [9].
TLR4 also mediates to induce nitric-oxide synthase
(iNOS), and soluble guanylate cyclase (sGC) trough
MyD88 and Trif activation pathways. Remarkably, nitric
oxide is implicated as key intracellular mediators respon-
sible for both ischemic preconditioning, which promotes
cell survival pathway through both cGMP-dependent and
cGMP-independent/ caspase-3 nitrosylation mechanisms.
The sGC is downstream main effector of nitric oxide and
responsible for nitric oxide-elicited biological effects. Nitric
oxide binds to the heme moiety of sGC and activate the en-
zyme to generate cGMP (Fig. 2) [43, 44].
TLR9 preconditioning reprograms the subsequent
responces to TLRs
From the in vivo experiments, it has been discovered that
stimulation of TLR9 with its ligands would be the most po-
tent method to attenuate the pro-inflammatory response tothe other TLR ligands [45, 46]. Accordingly, TLR9 precon-
ditioning by CpG-DNA (ODN) attenuates ischemic injuries
in the brain and liver, through down-regulation of NF-κB
pathway and its transcriptional activity [4, 47]. TLR9 agon-
ist ODN attenuates myocardial I/R injury and protects cells
against spontaneous apoptosis and prevents trauma-
hemorrhage which causes cardiac dysfunction, through
activation of PI3K/Akt signaling pathway [17]. The pre-
treatment of mice with TLR9 ligand significantly de-
creases myocardial infarct size and improves cardiac
function after I/R events, which indicating TLR9 cardio
protective effects against I/R injuries [48]. In I/R and
septic mice model, systemic administration of ODN,
72 h prior to brain ischemia reduced ischemic damage
up to 60 % [24]. It has been discovered that preconditioning
with TLR9 ligand would be a potent tool to reprogram the
subsequent TLR2/4/5-stimulation response, in vivo. Despite
the well-defined role of TLR2 and TLR4 in protection
against I/R injuries, but TLR9 poses a particular role in pro-
tecting both heart and brain [18, 23].
The CpG-DNA administration, either as pretreatment
or by continuous infusion after the onset of cardiac is-
chemia, significantly improve LVEF after I/R injury and
was observed to attenuate inflammatory cardiac dysfunc-
tion, while the same administration induced no detect-
able change in cardiac physiology in healthy models.
According to the models, TLR9 agonist ODN activates
both NF-κB and PI3K/Akt signaling pathway and their
transcriptional activity. Activation of NF-κB pathway,
however, on its own is able to explosively turn on a
broad set of inflammatory cellular programs, because of
its powerful nature, but there are a number of negative
feedback mechanisms in place to control NF- κB path-
way [49].
Herein, TLR moderate activation would inhibit inflam-
matory pathway and biases signaling toward the PI3K/
Akt pathway via inducing the NF-κB pathway inhibitors
TNFAIP3, its associated protein TNIP1, NFKBIA, and
also an additional inhibitor TRIM30a, which are further
up-regulated by activated PI3K/Akt pathway to protects
cells against apoptosis [45, 46].
The mechanism for down-regulation of NF-κB path-
way and its cross talk with PI3K/Akt signaling pathway
is according to the several reports and their assumed
model for pathway activation (Fig. 3) [4, 45–47].
The PI3K/Akt signaling pathway acts as an endogen-
ous negative feedback regulator and/or compensatory
mechanism, to limit pro-inflammatory and apoptotic
events in response to injurious stimuli. Recently, a cross
talk between TLR signaling and the PI3K-α/Akt pathway
have been identified [16, 50, 51].
In the preconditioning mechanism, TLR9 signaling
acts as a dominant activator of the isoform PI3Kα-Akt
pathway during I/R injury [17, 22].
Fig. 2 TLR preconditioning triggers cross activation of both MyD88-dependent and Trif-dependent pathways with PI3K/Akt. TLR3 exclusively, and
TLR4 partly signals via Trif-dependent pathway. A proposed mechanism for the TLR4-MyD88-dependent mechanism to protect against cardiac I/R.
TLR4 activation by its ligand, leads to MyD88-dependent iNOS induction and increased NO production. NO protects myocardium via sGC- and
cGMP/PKG-dependent mechanisms. Trif is not required for the TLR4-NO-mediated cardiac protection. LPS, lipopolysaccharide; iNOS, inducible
nitric-oxide synthase; MyD88, myeloid differentiation factor 88; sGC, soluble guanylate cyclase; PKG, protein kinase G; TLR, toll-like receptor; Trif,
TIR-domain-containing adaptor protein inducing interferon-β–mediated transcription factor
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Fig. 3 A negative feedback cross talk between PI3Kα/Akt and NF-κB signaling pathway by a local brief stimulation of TLR9, a potent preconditioning tool
for programming the subsequent responses to I/R injuries and stimulation by TLR2, TLR4, or TLR5 ligands. TLR9 ligation with CpG-DNA leads to receptor
tyrosine phosphorylation and subsequent activation of the p85 subunit of PI3K. The PI3K-α/Akt pathway is subsequently activated in response to TLR9
ligation. Activation of PI3K/Akt pathway protects cells against apoptosis, through up-regulation of the NF-κB pathway inhibitors TNFAIP3/TNIP1/NFKBIA/
TRIM30. TLR9 agonist activates both NF-κB and PI3K/Akt signaling pathway. TLR moderate activation directs to PI3K/Akt pathway through up-regulating
NF-κB pathway inhibitors TNFAIP3, its associated protein TNIP1, NFKBIA, and also an additional inhibitor TRIM30a, to inhibit inflammatory
pathway. Activation of PI3K/Akt signaling protects cells against apoptosis, through further up-regulation of the NF-κB pathway inhibitors
TNFAIP3/TNIP1/NFKBIA/TRIM3. TLR9 signaling acts as a dominant activator of the isoform PI3Kα-Akt pathway during I/R injury and in the
preconditioning mechanism
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family of signal transduction enzymes protecting spe-
cially myocardium from I/R injuries [52]. According to
the references, TLR9-ligation preconditioning would
lead to the activation of PI3K-α/Akt pathway, via causing
tyrosine phosphorylation of the receptor and subsequent
association of the PI3K subunit p85 (Fig. 3) [17–19, 50].
The PI3Kα isoform antagonizes pathological cardiac
hyperthrophy and belongs to class IA PI3Ks which are notactivated by GPCRs, but are activated by insulin-like
growth factor-1 (IGF-1) or other tyrosine kinase receptors/
cytokine receptors [53, 54]. Physiological cardiac growth is
performed by class IA PI3Ks pathway including PI3Kα,
PI3Kβ and PI3Kδ [54]. Remarkable, the transgenic PI3Kα
mice are resistant to pathological cardiac hyperthrophy and
cardiac dysfunction induced by pressure overload [21]. Ap-
parently, the ODN mechanism for in vivo cardioprotection
lies in the up-regulation of PI3K-p110α/p-Akt to protects
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reflected in reduced infarct size and in inhibition of cardiac
cell death in rats [50, 51].
Whereas, The G protein-coupled receptor (GPCRs)-
depended signaling pathway activaties tha PI3Ks (PI3Kγ)
that belongs to the class IB, a heterodimers of p110γ and an
adaptor subunit. The activated class IB PI3Ks are respon-
sible for the prohypertrophic effects of hypertrophic agents
noradrenaline, angiotensin II, and endotheilin-1. The Gβγ
subunit of G proteins is associated with activated class IB
PI3Ks (PI3Kγ) [55]. The activated prohypertrophic PI3Kγ,
in turn cross talks with downstream signaling mediators
Akt/ERK1/2. Noteworthy, mouse model with genetic
knockout of PI3Kγ is resistant to isoproterenol-induced
pathological cardiac hyperthrophy and heart dysfunction,
accompanied by attenuated activation of Akt and ERK1/2
pathways [55].
Finally, ODN administration also leads to increased
levels of phospho-ERK and activation of the Raf/MEK/
ERK signaling pathway [56]. Activation of Raf/MEK/ERK
pathway causes anti-apoptotic effects through mechan-
ism involving Bim/BCL2/Bax. Both, the Raf/MEK/ERK
and PI3K/Akt pathways are synergistically regulated and
there is a positive crosstalk between them [57].
Thereby, preconditioning with TLR ligands can emerge
an early expression of NF-κB inhibitors which suppress late
inflammatory responses and repressing further TLR stimu-
lation [45, 46].
Release of DAMPs and positiv- feedback-regulation loop
of TLR signaling
All known TLRs are expressed in the heart, whose stimula-
tion results in a NF-κB mediated pro-inflammatory re-
sponse and decreased contractility [58]. In the early phase,
these receptors signal predominantly through the ubiqui-
tous transcription factor, NF-κB [59].
After open heart surgery, in chronic pressure overload
and in patients with unstable angina or in patients with
acute myocardial infarction, DAMPs such as HSP60,
HSP70 and HMGB1 are released and signaling through
putative receptors TLR2 and TLR4 [60, 61].
In response to chronic stimulation, TLR2 and TLR-4
mediate up-regulation of cardiac TNF-α, IL-1β, and NO
and induction of adaptive cardiac hypertrophy [62, 63].
As stress response biomarkers, HMGB1, HSP60 and
HSP70 mediates activation of NF-κB and synthesis of pro-
inflammatory cytokines IL-1ß and TNF-α [64], in a 2-step
mechanism, in the first step response, IL-1ß and TNF-α are
induced, required for the second step response in which
IL-6 is induced. The first step response contribute to car-
diac adaptation to pressure overload, whereas sustained
pressure overload and resultant prolonged inflammatory re-
sponses induce a shift to the second step response and IL
6–dominant inflammation, which cause adverse cardiacremodeling and heart failure. Because of a positive feedback
loop between NF-κB activity and IL-1ß, the over activation
of TLR4 or TLR2/NF–κB pathway would lead to cardiac
hypertrophy [65].
In acute phase, alarming biomarkers such as HMGB1 are
released from damaged cells and also from activated plate-
lets which causes inhibition of mesenchymal stem cells
(MSCs) migratory responses via stimulation of TLR2/TLR4
expressed on MSCs. HMGB1 for example activates both
TLR2/TLR4 and the transmembrane multi-ligand receptor
of immunoglobulin superfamily [66, 67].
Following cardiac injury such as in myocardial infarc-
tion, serum level of HMGB1is significantly increased,
peaking 12 h after infarction, and is associated with ad-
verse clinical outcomes including pump failure, cardiac
rupture, and in-hospital cardiac deaths [61, 68].
HMGB1/TLR4 interaction causes down-regulation of
growth factor signaling which interfere with recruitment of
MSCs following cardiac injury [61, 68]. Prevention of MSC
recruitment to apoptotic site is in part driven by down-
regulation of hepatocyte growth factor (HGF) receptor
MET on MSCs. HGF is known to be anti-apoptotic [69],
pro-angiogenetic [70], and immunosuppressive [71] which
confer cardioprotection [72].
Bone marrow MSCs play a critical role in tissue repair
and contribute to myocardial recovery [68]. Thereby,
blocking TLR4 improves efficacy of MSC-based therapy
and their infiltration into the damaged target tissue. It
seems a novel mechanism for myocardial repair and re-
generation [66].
However, a completely abolished inflammatory response
is detrimental for repair events because inflammation is
critical for proper wound healing [73, 74]. For example, cor-
ticosteroid administration reduces IS but results in
aneurysm formation and rupture of the myocardium after
infarction. But, programmed activation of TLRs axis in-
duces IGF-1 signaling [8], whereupon contributes to adap-
tive cardiac function in response to pressure overload,
performed by class IA PI3Ks pathway including PI3Kα,
PI3Kβ and PI3Kδ [8, 75, 76].
In addition, miR-146 which is up-regulated by TLR4
and pro-inflammatory stimuli IL-1 and TNF-α [77], in a
negative-feedback-regulation loop is able to negatively
control TLR4 pathway and its downstream cytokine sig-
naling, in human cells. MiR-146 directly targets the
NF-κB-dependent genes IRAK1 and TRAF6 (the key
kinases downstream of TLR4 signaling) [78, 79]. The im-
pairment of IRAK1/TRAF6 regulation by miR-146 would
result in prolonged activation of TLR4 and its downstream
signaling, which resulting CAD pathogenesis.
Conclusions
In organ I/R injuries, in hemodynamic stresses and in re-
sponse to pressure overloads, conventional TLR-NF-κB
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pathway initiates an immune response which could result
in the failing of affected organ. DAMPs signals (HMGB1,
HSPs, oPL) released from damaged cells or ischemic/reper-
fused tissues, interact with TLRs which subsequently acti-
vate NF-κB inflammatory pathway. In a manner mimicking
the ischemic/anesthetic cardiac preconditioning, all TLRs
are able to limit pro-inflammatory and apoptotic events in
response to injurious stimuli by a compensatory mechan-
ism which involving PI3K/Akt pathway to protect from I/R
injuries. The protection would be depended on the intracel-
lular signaling mediators MyD88 and Trif, through a cross
talk mechanism between TLR-NF-κB and PI3K/Akt signal-
ing pathways. The proposed preconditioning mechanism
involves the PI3K/Akt signaling pathway to attenuate the
subsequent robust stimulation of TLR-NF-κB pathway. In
summary, programmed ligation of TLRs would trigger a
preconditioning mechanism to protect ischenic heart
against I/R injuries .
TLR agonist programmed preconditioning, significantly
decreases I/R-induced damages and improves cardiac func-
tion following myocardial I/R event. Hence, programmed
activity of TLR pathway would hold a great promise in the
new therapeutic approach for I/R injuries.
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